MedTrace Logo

Low Concentration Atropine in the Prevention of Myopia in Children.

NCT05939882 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 428

Last updated 2023-07-11

No results posted yet for this study

Summary

This double-blind, randomized controlled clinical study is to evaluate the effectiveness and safety of low concentration atropine in preventing myopia in pre-myopia children, and to explore whether there is a dose effect relationship between different concentrations of atropine in preventing myopia.

Conditions

  • Myopia, Progressive

Interventions

DRUG

low concentration atropine (0.01%)

low concentration atropine (0.01%)

DRUG

low concentration atropine (0.02%)

low concentration atropine (0.02%)

DRUG

low concentration atropine (0.04%)

low concentration atropine (0.04%)

DRUG

Placebo

Placebo eye drop

Sponsors & Collaborators

  • Shanghai Eye Disease Prevention and Treatment Center

    lead OTHER

Principal Investigators

  • He Xiangui · Shanghai Eye Disease Prevention and Treatment Center

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
6 Years
Max Age
9 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-04-01
Primary Completion
2024-04-30
Completion
2024-04-30

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05939882 on ClinicalTrials.gov